Goldberg I
Aust N Z J Ophthalmol. 1987 May;15(2):97-107. doi: 10.1111/j.1442-9071.1987.tb00053.x.
In glaucomatous eyes refractory to medication, laser techniques and conventional drainage surgery, intraocular pressure is often high, and visual loss rapid. In this situation a reliable, robust artificial outflow system is required. Molteno has evolved a plastic tube and plate device combined with a fibrosis suppression medication regimen. Thirty-eight eyes of 32 patients with uncontrolled glaucoma were treated with the Molteno system. Six months after operation mean intraocular pressure had been reduced from 41.0 +/- 13.6 to 16.2 +/- 5.6 mmHg. Eighteen eyes had pressures of 20 mmHg or less on no hypotensive therapy, 17 on reduced treatment. Three eyes had a pressure of 21 to 35 mmHg on treatment at six months. The 13 aphakic eyes responded as well as 25 phakic eyes. Five eyes with rubeotic glaucoma demonstrated pressures of less than 20 mmHg without therapy, four eyes with traumatic glaucoma required continuing medication with three having pressures below 22 mmHg. Of the seven eyes with uveitic glaucoma, one was lost, two required maintenance therapy; five of six surviving eyes had pressures below 20 mmHg. Fifteen eyes with congenital or juvenile glaucoma achieved pressures below 20 mmHg, three of these with timolol drops, three with timolol and acetazolamide, and nine with no treatment. While seven of seven eyes with refractory primary open-angle glaucoma attained pressures below 20 mmHg, all seven needed continuing mild hypotensive therapy. Eleven eyes underwent a one-stage procedure, while 27 eyes required a two-stage operation. Twenty-eight eyes received fibrosis suppression medication after the second stage, and 24 maintained or improved their preoperative visual acuity. Results have been encouraging: in general the Molteno system is recommended as the second drainage operation in all glaucomatous eyes in which conventional therapy has failed, and as the primary surgical procedure (after laser techniques) in eyes with rubeotic and uveitic glaucoma. Ciliary body destructive procedures should be restricted to control of symptoms in blind eyes.
在对药物治疗、激光技术和传统引流手术均无反应的青光眼眼中,眼压往往很高,视力丧失迅速。在这种情况下,需要一个可靠、有效的人工引流系统。莫尔滕诺研发出一种塑料管和引流盘装置,并结合了抑制纤维化的药物治疗方案。32例青光眼控制不佳的患者的38只眼睛接受了莫尔滕诺系统治疗。术后6个月,平均眼压从41.0±13.6 mmHg降至16.2±5.6 mmHg。18只眼睛在未进行降压治疗的情况下眼压降至20 mmHg或更低,17只眼睛在减少治疗的情况下眼压得到控制。3只眼睛在术后6个月接受治疗时眼压为21至35 mmHg。13只无晶状体眼的反应与25只有晶状体眼相同。5只新生血管性青光眼眼睛在未治疗的情况下眼压低于20 mmHg,4只外伤性青光眼眼睛需要持续用药,其中3只眼压低于22 mmHg。在7只葡萄膜炎性青光眼眼睛中,1只失明,2只需要维持治疗;6只存活眼睛中的5只眼压低于20 mmHg。15只先天性或青少年性青光眼眼睛眼压降至20 mmHg以下,其中3只使用噻吗洛尔滴眼液,3只使用噻吗洛尔和乙酰唑胺,9只未进行治疗。虽然7只难治性原发性开角型青光眼眼睛眼压均降至20 mmHg以下,但所有7只眼睛都需要持续进行轻度降压治疗。11只眼睛接受了一期手术,而27只眼睛需要二期手术。28只眼睛在二期手术后接受了抑制纤维化的药物治疗,24只眼睛维持或提高了术前视力。结果令人鼓舞:一般来说,对于所有传统治疗失败的青光眼眼睛,莫尔滕诺系统推荐作为二次引流手术;对于新生血管性和葡萄膜炎性青光眼眼睛,推荐作为主要手术方法(在激光技术之后)。睫状体破坏性手术应仅限于控制盲眼的症状。